P32 SODIUM PHOSPHATE — phosphorus p-32 injection, suspension
Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
AnazaoHealth’s compounded P32 Chromic Phosphate is supplied as a sterile, nonpyrogenic aqueous solution. It contains 30 % dextrose solution, 1 mg sodium acetate, 2 % benzyl alcohol added as a preservative. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.
INDICATIONS AND USAGE
P32 chromic phosphate is indicated for intracavitary instillation for the treatment of peritoneal or pleural effusions caused by metastatic disease, and may be injected interstitially for the treatment of cancer. It is also used in hemophilia patients for intraarticular injections.
Radioactive phosphorous works by local irradiation by beta emission.
P32 sodium phosphate should not be used in the presence of ulcerative tumors.
Not for intravascular injection.
Shake the vial well before injection.
For intraperitoneal instillation, administer 10-20 mCi
For intrapleural instillation, administer 6 to 12 mCi
Doses for interstitial use should be based on estimated gram weight of tumor, about 0.1 to 0.5 mCi/gm.
| P32 SODIUM PHOSPHATE |
p32 sodium phosphate injection, suspension
|Labeler — AnazaoHealth Corporation (011038762)|
|AnazaoHealth Corporation||011038762||MANUFACTURE (51808-127)|
Revised: 06/2012 AnazaoHealth Corporation
RxDrugLabels.com provides trustworthy package insert and label information about marketed prescription drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by RxDrugLabels.com. Every individual prescription drug label and package insert entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.